PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 14, 2026JAMA Network Open3 citationsOpen Access

KRAS Variant Frequency and Colorectal Cancer–Specific Survival by Race and Ethnicity

View Full Paper
GRGladys Magaly RodriguezMAMayada AljehaniDDDylan DePuy

Key Points

  • This study examines the impact of race and ethnicity on KRAS variant frequency and colorectal cancer-specific survival.
  • Cross-sectional study design
  • Analysis of colorectal cancer patients by race and ethnicity
  • Comparison of KRAS variant prevalence and survival outcomes among groups.
  • Hispanic and non-Hispanic Black patients showed higher KRAS variant prevalence than non-Hispanic White patients.
  • Non-Hispanic Black patients with KRAS variants had worse survival compared to non-Hispanic White patients.
  • Hispanic patients with wild-type KRAS had worse survival compared to non-Hispanic White patients.

Abstract

In this cross-sectional study of patients with colorectal cancer, Hispanic patients and non-Hispanic Black patients had higher KRAS variant prevalence than non-Hispanic White patients. Among patients with a KRAS variant, non-Hispanic Black patients had worse cause-specific survival than non-Hispanic White patients. Among patients with wild-type KRAS, Hispanic patients had worse survival compared with non-Hispanic White patients. These findings highlight the need for further research on racial and ethnic differences in KRAS-related outcomes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rodriguez et al. (2026) studied this question.

synapsesocial.com/papers/69b4ada918185d8a39801639https://doi.org/10.1001/jamanetworkopen.2026.1585
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Association of genetic ancestry with molecular tumor profiles in colorectal cancer2024 · 19 citations
  2. 2KRAS Sequence Variation as Prognostic Marker in Patients With Young- vs Late-Onset Colorectal Cancer2023 · 14 citations
  3. 3Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States2022 · 76 citations
  4. 4Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer2014 · 612 citations
  5. 5American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy2009 · 1,158 citations